Context Therapeutics (CNTX) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NextCure (NXTC) has outperformed Context Therapeutics (CNTX) over the past year, losing 1.0% versus a loss of 73.8%. NextCure is the larger company by market cap ($31.0 million vs $27.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | NXTC |
|---|---|---|
| Share price | $0.299 | $6.78 |
| Market cap | $27.47M | $31.03M |
| 1-day change | -4.35% | +3.35% |
| YTD return | -79.66% | -52.22% |
| 1-year return | -73.77% | -1.02% |
| 5-year return | — | -93.74% |
| EPS (TTM) | $-0.48 | $-8.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.62 | $15.74 |
| 52-week low | $0.2954 | $1.55 |
| Distance from 52-week high | -91.74% | -56.93% |
| Average volume | 1.83M | 2.11M |
| Shares outstanding | 91.88M | 4.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed CNTX by 72.8 percentage points over the past year.
CNTX vs NXTC FAQ
Which is bigger, Context Therapeutics or NextCure?
NextCure (NXTC) is larger, with a market capitalization of $31.03M compared with $27.47M for Context Therapeutics (CNTX).
Which stock has performed better over the past year, CNTX or NXTC?
NXTC returned -1.02% over the past 12 months, compared with -73.77% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.